StockPreacher.com announces investment report featuring GenVec

April 22, 2016

None of the children with herpes zoster had serious illness requiring hospitalization. Another recent study in the Pediatric Infectious Disease Journal (December, 2009) found that children receiving varicella vaccine are much less likely to develop herpes zoster than those with natural chickenpox and that, when the condition does occur, it is less severe.The lower risk in black children is consistent with previous studies showing that rates of herpes zoster are lower in black than white adults. ...

Ichor, Profectus announce agreement for clinical development of DNA vaccine programs

April 21, 2016

Dr. John Eldridge, Profectus Chief Scientific Officer, stated, ???We are excited to be entering into the clinic using Ichor??s TriGrid?? delivery system for the delivery of our DNA vaccines both alone, and in prime/boost combination with our rVSV vaccine vector. Profectus has made significant clinical progress in advancing our vaccine programs using this multi-pronged approach. We believe that by combining our proprietary DNA vaccine tech...

Peripheral nerve stimulation promising for treatment of post-herpetic neuralgia

April 20, 2016

Two octopolar St. Jude Medical leads were implanted subcutaneously to the left of the patient's midline. Leads were tunneled subcutaneously to a location in the upper left buttock and a pocket was produced under the skin where a rechargeable generator was implanted. Two weeks after surgery the stimulator was turned on and the patient was given a remote which enabled him to turn it on and off himself. At a two-month follow-up appointment the patient's pain medication use was decreased to 10 mg of...

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

April 19, 2016

???NP-1??s orphan drug designation is another indication of the significant need that exists for new and more effective treatment options for patients suffering from PHN,??? remarked Jack Talley, President and Chief Executive Officer of EpiCept. ???Our recent Phase IIb study of NP-1 in the PHN indication demonstrated that it has at least equivalent efficacy to the unit market leader, gabapentin, which we believe is a strong indicator of it...

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

April 18, 2016

The shares and warrants offered in the private placement, and the shares issuable upon the exercise of the related warrants, have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the SEC or through an applicable exemption from SEC registration requirements. The shares and warrants were offered only to accredited investors. This news release shall not constitute an offer to...